Monday, March 3, 2014
Theravance Announces Update to Planned Separation of Late-Stage Partnered Respiratory Assets from Biopharmaceutical Operations
Tuesday, February 25, 2014
Theravance to Present at Investor Conferences in March 2014
Thursday, February 20, 2014
Anoro« (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD
Medicines that make a difference┬«
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
We partner with pharmaceutical companies to accelerate development and commercialization of our product candidates.
Every day at Theravance, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance discovers, develops and brings important medicines to patients by: